Curated News
By: NewsRamp Editorial Staff
August 07, 2025
ARTBIO Strengthens Leadership with Four New Board Members to Advance Cancer Therapies
TLDR
- ARTBIO's strategic board appointments enhance its competitive edge in advancing alpha radioligand therapies, leveraging world-class expertise for growth and innovation in cancer treatment.
- ARTBIO appoints four experts to its Board, each bringing specialized knowledge in biotech investment, healthcare strategy, operations, and capital markets to methodically guide the company's expansion.
- ARTBIO's new board and advisory team aims to accelerate cancer therapies, promising a future with more effective and safer treatments for patients worldwide.
- Discover how ARTBIO's innovative AlphaDirect technology and expert team are pioneering a new era in cancer care with alpha radioligand therapies.
Impact - Why it Matters
This news is significant as it highlights ARTBIO's strategic moves to enhance its leadership team with experts who bring a wealth of experience in biotech investments, healthcare, and operations. Their collective expertise is expected to accelerate the development of ARTBIO's innovative alpha radioligand therapies, potentially offering new hope for cancer patients. The transition of co-founder Roy Larsen to a Technical Advisory Board role ensures that his pioneering work in radiopharmaceuticals continues to influence the company's direction and the broader field of cancer treatment.
Summary
ARTBIO, Inc., a pioneering clinical-stage radiopharmaceutical company, has announced the appointment of four distinguished professionals to its Board of Directors, marking a significant step in advancing its alpha radioligand therapies (ARTs). The new members include Maha Katabi, Ph.D., CFA, a General Partner at Sofinnova Investments; Robert Mittendorff, M.D., MBA, General Partner and Head of Healthcare at B Capital Group; Julie O’Neill, MBA, an experienced healthcare leader; and Gabe Gelman, Head of Capital Solutions at Baker Bros. Advisors LP. These appointments follow ARTBIO's recent Series B funding round and are aimed at leveraging the appointees' vast experience to guide the company's strategic growth and program expansion. Additionally, co-founder Roy Larsen, Ph.D., will transition from the Board of Directors to a newly established Technical Advisory Board, continuing his invaluable contribution to the field of radiopharmaceuticals.
ARTBIO is at the forefront of developing a new class of cancer therapies using its AlphaDirect technology, which enables the reliable production and delivery of ARTs. The company's lead program, AB001, targeting metastatic castration-resistant prostate cancer, is currently in first-in-human trials. This strategic expansion of the board underscores ARTBIO's commitment to innovation and its mission to redefine cancer care through groundbreaking alpha radioligand therapies. For more insights into ARTBIO's revolutionary work, visit ARTBIO, Inc. and follow their progress on LinkedIn.
Source Statement
This curated news summary relied on content disributed by citybiz. Read the original source here, ARTBIO Strengthens Leadership with Four New Board Members to Advance Cancer Therapies
